La voie de signalisation MET et son implication thérapeutique dans les cancers digestifs

摘要: The MET receptor tyrosine kinase and its ligand HGF regulates many signalling pathways involved in proliferation cell motility, invasion angiogenesis. Deregulation of HGF-MET system by different biological mechanisms may contribute to the tumour development types cancers. Some pharmacological approaches have been developed inhibit pathway, using monoclonal antibodies against or MET, inhibitors receptor. In digestive cancers, several clinical studies evaluated safety efficacy these targeted therapies, with some promising results but requiring confirmation phase III trials. Moreover, it appears that expression could be a predictive marker response therapies for gastrointestinal tumours. Thus, somatic alterations represent interesting therapeutic targets help select patients who can favourably respond such treatment.